Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 October 2019Website:
http://www.tffpharma.comNext earnings report:
15 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:49:09 GMTDividend
Analysts recommendations
Institutional Ownership
TFFP Latest News
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.
TFF Pharmaceuticals, Inc. (TFFP) reported a quarterly loss of $2.40 per share, which was higher than the expected loss of $2.20 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $4.75 per share reported a year ago.
FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy. Data being presented at the AAAM Conference were first disclosed by the Company in December 2023.
Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis - IR, LifeSci Advisors Harlan Weisman - CEO Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Daniel Carlson - Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.
FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will attend and hold one-on-one investor meetings at the upcoming Jones Trading 2023 Healthcare Summit. Dr. Weisman will also present and hold one-on-one investor meetings at the upcoming Roth MKM 2023 Healthcare Opportunities Conference.
What type of business is TFF Pharmaceuticals?
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
What sector is TFF Pharmaceuticals in?
TFF Pharmaceuticals is in the Healthcare sector
What industry is TFF Pharmaceuticals in?
TFF Pharmaceuticals is in the Biotechnology industry
What country is TFF Pharmaceuticals from?
TFF Pharmaceuticals is headquartered in United States
When did TFF Pharmaceuticals go public?
TFF Pharmaceuticals initial public offering (IPO) was on 25 October 2019
What is TFF Pharmaceuticals website?
https://www.tffpharma.com
Is TFF Pharmaceuticals in the S&P 500?
No, TFF Pharmaceuticals is not included in the S&P 500 index
Is TFF Pharmaceuticals in the NASDAQ 100?
No, TFF Pharmaceuticals is not included in the NASDAQ 100 index
Is TFF Pharmaceuticals in the Dow Jones?
No, TFF Pharmaceuticals is not included in the Dow Jones index
When does TFF Pharmaceuticals report earnings?
The next expected earnings date for TFF Pharmaceuticals is 15 August 2024